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Controversy about proconvulsant and anticonvulsant nitric oxide
(NO) effects and the place of oxidative stress in convulsions, are still a
matter of research. We investigated the interaction between 2-amino-5-
phosphonovaleric acid (APV), a competitive N-methyl-D-aspartate
(NMDA) receptor antagonist, and N-nitro-L-arginine methyl ester (L-
NAME), a nonselective nitric oxide synthase (NOS) antagonist, in penty-
lenetetrazole (PTZ)-induced convulsions. Pentylenetetrazole was ap-
plied to adult Wistar rats intraperitoneally (ip), in a single dose of 80
mg/kg, and L-NAME (10 µg/10 µl) or APV (20 µg/10 µl) intracerebroven-
tricularly (icv), 30 and 10 minutes before PTZ, respectively. In the same
manner, another group received both antagonists. Control animals
were given 0.9% saline.
N-nitro-L-arginine methyl ester exerted a weak anticonvulsant
effect, preventing generalized clonic (GCC) and clonic-tonic convul-
sions (CTC) in 17% of cases. With APV protection against GCC and CTC
was 100%, forelimb dystonia (FLD) was decreased in 33% of cases,
and time to onset of all convulsive patterns was prolonged (p<0.05 to
0.01). All effects of APV, except in CTC, were reversed by L-NAME ap-
plied prior to APV.
In APV-PTZ treated animals, superoxide anion content was in-
creased in the forebrain cortex, striatum and hippocampus, without an
overwhelmed antioxidative superoxide dismutase (SOD) defence sys-
tem in the other treatments. When the APV-PTZ group was treated with
L-NAME, both SOD activity and superoxide anion content were addi-
tionally decreased, indicating that the NOS-NO system was involved in
the metabolism of superoxide anions.
It is suggested that clinical and biochemical effects of NO stron-
gly depend upon the pretreatment and might lead to a wrong impres-
sion of NO contradictory activity.
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INTRODUCTION
The complex biochemical and structural heterogeneity of epilepsies and un-
satisfactory understanding of their pathophysiological mechanisms, are a consid-
erable scientific, clinical and pharmacological challenge. Better understanding of
the cellular and molecular basis would make possible the development of more
effective antiepileptics and antiseizure drugs, that would improve the prevention
and treatment of epilepsy.
Imbalance between excitatory amino acids (EAK) and gamma aminobutyric
acid (GABA) is the cornerstone in epileptogenesis. There are a number of data
about convulsions induced by EAK, acting on different receptor sites (Tutka et al.,
1996), or induced by GABA antagonists, with some new insights in to the GABAer-
gic role in the EAK-GABA interaction (Kohling, 2002).
There is no doubt that nitric oxide (NO), which is released by glutamate, is
involved in the pathogenesis of convulsions, but the results remain conflicting.
Proconvulsant (Gross et al., 1994; Jayakumar et al., 1999) and anticonvulsant ef-
fects (Lallement et al., 1996) have been registered. It was also found that NO does
not influence epileptogenesis (Czuczwar et al., 1999). Many of these disagree-
ments came from unstandardized definitions of convulsions and differences in the
choice of experimental model and experimental animals.
Besides unequivocal results about the role of NO in several animal convul-
sion models, data about the place of NO in pentylenetetrazole (PTZ)-evoked con-
vulsions are different. According to the results obtained, NO could be anticonvul-
sant (Nidhi et al., 1999), enhance some convulsive patterns (Del-Bel et al., 1997),
or be without any importance in clonic and tonic seizures (Przegalinski et al.,
1996; Hara et al., 1996).
It is obvious that the dose and the route of administration of PTZ and nitric
oxide synthase (NOS) antagonists, as well as the type of NOS isoenzyme antago-
nists, strongly affect the outcome of PTZ-evoked behaviour (Alexander et al.,
1998). That is why direct comparison between the convulsive responses of differ-
ent animal species in different experimental models (in vitro, ex vivo, in vivo) and
protocols is not suggested. Namely, great caution is required in order to escape
the conclusion trap.
Glutamate and NO are involved in physiological transmission and in the me-
tabolism of reactive oxygen and nitrogen species, such as superoxide anions, hy-
droxyl and NO radicals, and also in peroxynitrite (ONOO-) production (Crow and
Beckman, 1995). This is a stable and long acting toxic metabolite of NO and su-
peroxide anion that can produce a number of free radicals (Goss et al., 1999). It
may indicate that NO is a part of neuroprotective as well as neurotoxic processes.
In an attempt to investigate the potential clinical and biochemical interac-
tions between EAK and NO in seizures, we used chemically induced convulsions
in rats as an experimental model.
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MATERIAL AND METHODS
The experiments were performed on 13 week-old male Wistar rats (Rattus
norvegicus), housed in a temperature-controlled room (23±2oC), with a light/dark
cycle regulated to 11:13 hours. The rats had free access to food and water. All ex-
periments were conducted within two weeks, between 10 am and 3 pm.
Surgery was performed under pentobarbital sodium anaesthesia (45 mg/kg
body weight-bw, Vetanarcol  , Werfft-chemie, Wien). For intracerebroventricular
(icv) drug application, a polyethylene plastic cannula was stereotaxically im-
planted into the left lateral ventricle (coordinates: 1.3 mm behind the bregma, 1.8
mm left from the midline suture, 3.7 mm ventral from the durra) (Paxinos and Wat-
son, 1982). A cannula was fixed to the skull with dental cement and two jeweller
screws. The postoperative recovery period lasted six days, after which the rats
(five groups with 6-7 rats in each) were assigned randomly to different drug treat-
ments. The route and the time of applying chemicals, dissolved in 0.9% saline,
were selected according to their pharmacokinetic characteristics.
Chemicals for icv and ip application were given in a volume of 10  l and 1
ml/kg, respectively. The control group received 0.9% saline icv, 30 and 10 minutes
before saline (ip). Pentylenetetrazole (PTZ, Sigma) was used as the chemocon-
vulsant. It was applied intraperitonally (ip) in a dose of 80 mg/kg bw 30 and 10
minutes after treatment with 0.9% saline (icv).
Thirty minutes before PTZ, 10  g of a nonselective NOS antagonist, N  -
nitro-L-arginine methyl ester (L-NAME, Sigma) was given to one group. Twenty
minutes later, it also received saline (icv).
A competitive N-methyl-D-aspartate (NMDA) receptor antagonist, 2-amino-
5-phosphonovaleric acid (APV, Sigma), was administered to another two groups,
in the dose of 20  g, 20 minutes after 0.9% saline or L-NAME. Ten minutes after
APV, both groups received PTZ.
During the four minutes after PTZ treatment, the appearance (incidence)
and the time to onset of convulsive patterns were recorded, such as forelimb
dystonia (FLD), generalized clonic (GCC) and clonic-tonic convulsions (CTC).
Thereafter, the rats were sacrificed by decapitation. Heads were frozen in liquid ni-
trogen, and stored at –70oC until the brain structures were required for assay.
Forebrain cortex, striatum and hippocampus were dissected in the cold and
prepared for the spectrophotometrical biochemical analyses.
Superoxide anion content was determined through the reduction of ni-
troblue-tetrazolium (Merck) in an alkaline, nitrogen saturated medium. Analysis
was performed at 515 nm (Sun and Zigman, 1978).
Superoxide dismutase (SOD) activity was measured as inhibition of epi-
nephrine autooxidation at 480 nm. After adding 10 mM epinephrine (Sigma), the
kinetics were monitored in sodium carbonate buffer (Serva) containing 0.1 mM
EDTA (Sigma) (Auclair and Voisin, 1985).
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STATISTICS
The incidence of convulsive responses was expressed as a percentage of
the total animals in the group. Student’s t-test of proportion was performed with
p<0.05 and p<0.01 as indicators of the statistical significance of differences. The
time to convulsive response was expressed as the mean  standard deviation
(SD) and was analysed by the Mann-Whitney U-test, using the same levels of sig-
nificance.
Biochemical data were expressed as the mean  standard deviation (SD)
and were compared by Students t-test and analysis of variance. Differences were
considered statistically significant at p<0.05 and p<0.01.
RESULTS
Contrary to the saline group, which was without any convulsive pattern, the
treated rats developed convulsions that appeared in a regular order: forelimb
dystonia (FLD), generalized clonic convulsions (GCC) followed by clonic-tonic
convulsions (CTC).
Pentylenetetrazole alone evoked convulsive patterns in all of the animals in
the group (100%) (Figure 1). The NOS antagonist (L-NAME) demonstrated a very
weak anticonvulsant activity, preventing the incidence of GCC and CTC in 17% of
cases.
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Figure 1. Influence of APV and L-NAME on PTZ-evoked convulsions (80 mg/kg)in rats (n=6-
7)
The incidence of convulsive responses is expressed as the percentage of affected
rats in the group; *(**): p<0.05 (0.01), significance vs. PTZ treated group (Student’s t-
test of proportion).
1FLD=forelimb dystonia, 2GCC=generalized clonic convulsions, 3CTC=clonic-tonic
convulsions
The APV application was particularly effective. It prevented the appearance
of GCC and CTC completely (p<0.01 for both). It was less successful with limbic
convulsions, which were prevented only in 33% of cases. The anticonvulsant ac-
tivity of APV was diminished by L-NAME administration before APV. This led to
FPD augmentation by 16% and GCC by 50% (p=0.07). Such treatment did not af-
fect CTC.
At the same time, when compared to the PTZ treated group, APV delayed
the onset of all convulsive patterns (p<0.05, 0.01 and 0.01 for FLD, GCC and CTC,
respectively) (Table 1). The time for FLD and GCC appearance was partly re-
versed by L-NAME.
Table 1. Time to convulsive onset in the PTZ (80 mg/kg)-treated rats (n=6-7)
Drug treatment (L-NAME
and APV: 10 and 20  g;
PTZ: 80 mg/kg)
Convulsive response latency time (seconds)
FLD1 GCC 2 CTC 3
PTZ 49.5±11.3 118.6±25.8## 131.7±35.6##
L-NAME+PTZ 57.7±11.9 125.3±68.3# 128.1±67##
APV+PTZ 140.8±89.6* 240.0±0** 240.0±0**
L-NAME+APV+PTZ 87.5±74.8 169.5± 82.4# 240.0±0**##
Values are expressed as means±SD. When there was no convulsive response, the latency was de-
fined as 240 seconds. *(**): p<0.05 (0.01), significance of difference from corresponding PTZ treated
group; #(##): p.05 (0.01), significance to corresponding APV+PTZ treated group (Mann-Whitney U-
test).
1FLD=forelimb dystonia, 2GCC=generalized clonic convulsions, 3CTC=clonic-tonic convulsions.
Parameters of oxidative stress and antioxidative defence changed rapidly
after PTZ application, taking a very short time course of alterations, i.e. four min-
utes only.
In the group treated with APV before PTZ, the content of superoxide anion
radical was increased (p<0.01) in all structures (Figure 2), and did not change in
parallel with SOD activity (Figure 3). The effects of APV on the superoxide anion
were reversed with L-NAME.
The activity of SOD was not changed in the cortex, but it was decreased in
the striatum and in the hippocampus of the APV treated group (p<0.01 for both
stuctures) (Figure 3). Furthermore, SOD activity was additionally decreased after
L-NAME pretreatment (p<0.01, compared to APV+PTZ treated group). The only
enhancement was registered in the hippocampus after PTZ application.
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Figure 3. Superoxide dismutase activity in PTZ-evoked convulsions (80 mg/kg) in rats
(n=6-7)
Values are expressed as means±SD; ª: p<0.05, significant in comparison to corre-
sponding saline treated group; *(**): p<0.05 (0.01), significanct comparison to cor-
responding PTZ treated group ; #(##): p<0.05 (0.01), significant in comparison to
corresponding APV+PTZ treated group (Student t-test)
Figure 2. Superoxide anion content in PTZ-evoked convulsions (80 mg/kg) in rats (n=5-7)
Values are expressed as means±SD; ª: p<0.05, significante with respect to corre-
sponding saline treated group; *(**): p<0.05 (0.01), significant wilt respect to corre-
sponding PTZ treated group; #(##):p<0.05 (0.01), significance to corresponding
APV+PTZ treated group (Student t-test)
DISCUSSION
In the applied experimental model and protocol, L-NAME only slightly re-
duced PTZ convulsive responses, in comparison to the very strong APV activity. It
prevented the appearance of GCC and CTC by 17%. These results are partly
confirm to our previous study (Jelenkovi} et al., 2002), when, with some differ-
ences in the applied experimental design, we found much stronger, dose depend-
ent, anticonvulsant effects of L-NAME on PTZ-evoked convulsions. CTC was influ-
enced CTC the most. This finding is in agreement with the results of Han and co-
workers (2000) of increased brain NO concentration during PTZ-evoked convul-
sions.
The appearance of GCC and CTC were totally prevented by APV. On the
other hand, FLD was very resistant to APV. It has been proposed that clonic-tonic
convulsions are generated in the brainstem (Willoughby, 1999), representing an
animal model equivalent to grand mal epilepsy in humans. Activation of the hippo-
campus and other limbic, as well as extralimbic structures (thalamus), is responsi-
ble for the appearance and the spread of limbic convulsions, with forelimb dysto-
nia as the part of their clinical characteristics. They correspond to complex partial
seizures in people (Mraovitch and Calando, 1999), which are difficult to control.
No treatment in our experiment could successfully prevent them.
Our results suggest that the anticonvulsant effects of APV are the result of
two processes: NMDA receptor blockade and the activity of the NOS-NO system,
since L-NAME pretreatment to some degree reversed the protective effects of
APV.
As a competitive NMDA antagonist, APV blocks NMDA, but not non-NMDA
and metabotropic receptors (Michaelis, 1998). Thus, in the APV treated group, in-
creased glutamate activity evoked by PTZ could activate non-NMDA and meta-
botropic receptors in glial cells, as well in neurons, with L-arginine supply to neu-
rons from the glial cells. Also, through these receptors, NO could be released from
nitrosothiols (Yamada and Nabeshima, 1998), allowing neuronal transmission, in-
cluding NO-mediated increase in GABA release from neurons (Ohkuma et al.,
1995). It was found that the GABA-releasing process in the hippocampus is L-
NAME dose-dependent (Getting et al., 1996). In our experiment, L-NAME applica-
tion could decrease NO production resulting in reduction of GABAergic activity,
that would diminish some anticonvulsant effects of APV. The relative resistance of
the hippocampus to the anticonvulsant effects of APV and L-NAME probably is
due to its neurochemical organization and richnes sin glutamate transmission,
since glutamate activity leads to NO synthesis through the glutamate-Ca-calmo-
dulin-NOS system. Also, this brain region is the most sensitive to PTZ (Ben-Ari, et
al., 1981). At the same time, the response of the brain antioxidative system to the
possible prooxidants (PTZ-glutamate-NO) was well balanced, followed by SOD
activity decrease.
In the APV-treated group, superoxide anion production was enhanced and
was dependent on the NOS-NO system. Besides the well known superoxide an-
ion activity in NO scavenging, there is evidence about NO-evoked increases in su-
peroxide anion content. A number of mechanisms are of interest, such as the me-
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tabolism of peroxynitrite and hydrogen peroxide, and increase of free iron (Beck-
man 1991). Also, NO is involved in cytochrome c oxidase blockade, the last step
in the respiratory chain, that is followed by superoxide anions leaking from mito-
chondria (Smoth et al., 1999).
Another important source contributing to the superoxide anion increase
could be nitration of tyrosine residues in Cu, Zn superoxide dismutase with
ONOO-, which would result in decline and insufficiency of the SOD defence
mechanism (Souza, 1999). In our experiment, that was not the reason for the in-
crease in superoxide anion content, as L-NAME additionally decreased it in the
APV+PTZ treated group.
Not only metabolites of NO, but, in some conditions, NOS by itself can also
produce superoxide anions (decrease of oxygen or arginine supply) (Vega-
Agapito et al., 1999). Whether directly, through NOS, or indirectly, through NO me-
tabolism, SOD, a superoxide anion scavenging enzyme, was only overwhelmed
in APV+PTZ treated rats in our experiment, and superoxide anion content was en-
hanced all brain regions.
In PTZ-evoked convulsions, APV exhibited a strong anticonvulsant effect
and increased superoxide anion in the brain, indicating that NMDA receptors are
involved in these kinds of convulsions. Some divergences in NO effects were reg-
istered at the clinical and biochemical level. Nitric oxide exerted a weak procon-
vulsant, and a stronger anticonvulsant activity. Also, NO did not influence super-
oxide anion and SOD activity when L-NAME was given before PTZ, but, when L-
NAME was applied before APV+PTZ, both parameters were decreased. Such
findings suggest that NO effects are closely dependent on the neurochemical
changes induced by the substances applied. This gives basis for further investiga-
tions.
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AZOT OKSID (NO) I ANTAGONIST NMDA RECEPTORA U KONVULZIJAMA
IZAZVANIM PENTILENTETRAZOLOM
JELENKOVI] ANKICA, JOVANOVI] MARINA, NINKOVI] MILICA, MAKSIMOVI] M i
BO[KOVI] B
SADR@AJ
Kontroverzni nalazi o prokonvulzivnim kao i antikonvulzivnim efektima azot
oksida (NO) i zna~aju oksidativnog stresa u konvulzijama, i dalje su predmet is-
tra`ivanja. U konvulzijama izazvanim primenom pentilentetrazola (PTZ), ispitivali
smo interakciju izme|u 2-amino-5-fosfovalerinske kiseline (APV), kompetitivnog
antagoniste N-metil-D-aspartat (NMDA) receptora i N  -nitro-L-arginin metil estra
(L-NAME), neselektivnog antagoniste azot oksid sintaze (NOS). Odraslim paco-
vima Wistar soja, PTZ je ubrizgavan intraperitonealno (ip) u jednoj dozi od 80
mg/kg.
Ostale supstance, L-NAME (10 µg/10 µl) i APV (20 µg/10 µl), primenjivale su
se intracerebroventrikularno (icv), i to L-NAME 30, a APV 10 minuta pre PTZ. Po is-
tom vremenskom principu, jedna grupa dobila je oba antagonista, a kontrolna
fiziolo{ki rastvor NaCl.
N -nitro-L-arginin metil estar ispoljio je slabo antikonvulzivno dejstvo,
smanjuju}i incidenciju generalizovanih kloni~nih (GCC) i kloni~no-toni~nih kon-
vulzija (CTC) za 17%. Za razliku od L-NAME, APV je spre~ila nastanak GCC i CTC
kod svih `ivotinja (100%), a incidencija klonusa prednjih nogu (FLD) smanjena je
za 33%. Istovremeno, primenom APV produ`eno je vreme od aplikacije PTZ do
pojave svih konvulzivnih tipova (p<.05 do 0.01). Primenom L-NAME pre APV,
umanjeni su efekti APV, pri ~emu je do{lo do pove}anja incidencije FLD i GCC za
16%, odnosno 50%.
U kori prednjeg mozga, strijatumu i hipokampusu, `ivotinja koje su dobile
APV+PTZ, do{lo do pove}anja koncentracije superoksidnog anjona. Aktivnost
superoksid dizmutaze ne prati ovaj skok. Njen dodatni pad u grupi tretiranoj sa L-
NAME pre APV+PTZ, ukazuje da je sistem NOS-NO uklju~en u metabolizam su-
peroksidnog anjona.
Dobijeni rezultati ukazuju da klini~ki i biohemijski efekti NO u velikoj meri
zavise od prethodno primenjenih supstanci i promena izazvanih njima, {to mo`e
da doprinose sticanju pogre{nog utiska o kontradiktornim dejstvima NO.
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